Xin Lang Cai Jing·2025-10-18 02:06Core Insights - The 2025 Sustainable Global Leaders Conference will be held from October 16 to 18 in Shanghai, focusing on sustainable development and industry upgrades [1] - Fosun Pharma's Chairman Chen Yuqing emphasized the significant advancements in China's innovative drug industry over the past decade, with R&D numbers increasing from 5% in 2014 to 30% in 2024, nearing the U.S. figure of 35% [3][5] - Fosun Pharma's innovative drug licensing transactions reached over $60 billion in the first half of 2025, surpassing the total for the entire year of 2024 [3] Group 1: Conference Overview - The conference is co-hosted by the World Green Design Organization and Sina Group, with support from the Shanghai Huangpu District Government [1] - Key discussions will include creating a sustainable development model in Shanghai and exploring new growth paradigms for the city's five centers [1] Group 2: Fosun Pharma's Innovations - Fosun Pharma invests approximately 5 billion RMB annually in R&D, accounting for nearly 17% of its total pharmaceutical revenue [3][5] - The company has launched 12 innovative drugs since 2019, with four new products and five indications introduced in the first half of this year [3][5] Group 3: Global Expansion and ESG Commitment - Fosun Pharma has transitioned from being an "agent" to an integrated "R&D-manufacturing-sales" model, exemplified by the establishment of the largest Asia-Pacific headquarters for the Da Vinci surgical robot [5][6] - The company has supplied over 420 million doses of artemisinin-based products globally, treating over 84 million severe malaria patients, primarily children under five [6] - Fosun Pharma holds an MSCI ESG rating of AA, leading the industry, and is the only Chinese pharmaceutical company listed in the 2025 Fortune China ESG Impact List [7]